Our team has developed a highly specific monoclonal antibody targeting an allosteric region of KLK4, a serine protease implicated in ovarian carcinoma progression. By combining structural biology, innovative immunization strategies, and computational modeling, we identified and characterized an antibody (ABS4) that not only effectively inhibits KLK4’s enzymatic activity but also significantly reduces proliferation and migration in aggressive ovarian cancer cells.

#CancerResearch#AntibodyTherapy#AllostericInhibition#KLK4
#OvarianCancer#StructuralBiology#ComputationalBiology
#MonoclonalAntibody#DrugDiscovery